Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Metered Pump in Testosterone Deficient Adult Male Subjects Under Fasting Conditions

An Open-Label, Randomized, Balanced, Single-Dose, Two Treatment, Four Period, Two Sequence Replicate Design, Bioequivalence Study Of Testosterone Topical Gel, 1.62% Metered Pump, Manufactured By Amneal Pharmaceuticals LLC With AndroGel (Testosterone Gel) 1.62% Metered-Dose Pump, Marketed By Abbvie Inc., In Testosterone-Deficient (Hypogonadal) Adult Male Subjects Under Fasting Conditions

Bioequivalence study comparing the rate and extent of testosterone absorption for a test formulation versus the reference product.

Study Overview

• Status: Completed
• Conditions: Hypogonadotropic Hypogonadism; Primary Hypogonadism
• Intervention / Treatment: Drug: AndroGel (testosterone gel) 1.62% Metered-Dose Pump; Drug: Testosterone Topical Gel, 1.62% Metered Pump

Detailed Description

To compare the rate and extent of testosterone absorption for a test formulation of Testosterone Topical Gel, 1.62% Metered Pump, manufactured with that of AndroGel® (testosterone gel) 1.62% Metered-Dose Pump, in normal, healthy, adult, testosterone-deficient (hypogonadal) human male subjects under fasting conditions.

• Study Type: Interventional
• Enrollment (Actual): 32
• Phase: Phase 3

Contacts and Locations

Study Locations

• United States
  • Florida
    • Miami Gardens, Florida, United States, 33169
      • Phase One Solutions, Inc.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years to 63 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: Male

Description

Inclusion Criteria:

• Healthy adult men with hypogonadism with testosterone levels <250ng/dL
• 18 to 65 years of age (inclusive)
• Have normal PSA < 4.0ng/mL
• Weighing a minimum of 50 kg and having a body mass index between 18.0 and 38.0 kg/m2.
• Good health as determined by medical history and lack of clinically significant abnormalities (other than hypogonadism).
• Vital signs, must be within the following ranges heart rate: 45-100 bpm; systolic BP: 90-150 mmHg; diastolic BP: 50-90 mmHg. Out-of-range vital signs may be repeated.

Exclusion Criteria:

• Is female
• History of allergy or sensitivity to AndroGel® or any component of drug or a related testosterone drug, Axiron®, Testim®, etc.
• History of allergy or intolerance to soy, soybean, and/or soy lecithin
• History of any drug or food hypersensitivity or intolerance which, would compromise the safety of the subject or the study.
• History or presence of clinically significant ocular, cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease or any othercondition that, would jeopardize the safety of the subject or the validity of the study results.
• Had no major surgery or illness within 3 months before screening.
• History or presence of benign prostate hypertrophy, prostate and/or breast cancer.
• Has tattooed, damaged, scarred skin or any skin condition on right or left upper arm and shoulder region that may affect absorption of drug.
• Has a clinically significant abnormal finding on the physical exam, medical history, electrocardiogram or clinical laboratory results at screening.
• Has been on a significantly abnormal diet during the 4 weeks preceding the first dose of study medication.
• Has donated blood within 56 days or plasma within 30 days prior to the first dose of study medication.
• Has participated in another clinical trial within 30 days prior to the first dose of study medication.
• Has used any over-the-counter medication, including nutritional supplements, within 7 days prior to the first dose of study medication.
• Has used any prescription medication including hormonal treatment and or supplement within 30 days prior to the first dose of study medication.
• No depot injections or drug implants within 3 months of first dose of study medication.
• Has been treated with any known drugs that are moderate or strong inhibitors/inducers of CYP enzymes such as barbiturates, phenothiazine, cimetidine, carbamazepine, etc., within 30 days prior to the first dose of study medication and that may impact subject safety or the validity of the study results.
• Has positive cotinine test and/or smoked or used tobacco products within 60 days prior to the first dose of study medication
• Has a positive urine screen for drugs of abuse
• Has positive alcohol breathalyzer test
• Has a positive test for Hepatitis B surface antigen, Hepatitis C antibody, or Human Immunodeficiency Virus (HIV) at screening or has been previously treated for Hepatitis B, Hepatitis C, or HIV infection.
• Any difficulty fasting or has any dietary restrictions such as lactose intolerance, vegan, low-fat, etc.
• Unavailable for any confinement days or scheduled visits.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: AndroGel; AndroGel (testosterone gel) 1.62% Metered-Dose Pump. One actuation 20.25 mg	Drug: AndroGel (testosterone gel) 1.62% Metered-Dose Pump
Experimental: Testosterone Gel; Testosterone Topical Gel, 1.62% Metered Pump. One actuation of 20.25 mg.	Drug: Testosterone Topical Gel, 1.62% Metered Pump

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
AUC0-t	Area under the concentration vs. time curve, from the time of first dosing to the time of the last measured concentration.	Pre-Deose: -1 hour, -0.5 hour and Post-Dose 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 32, 36, 40, 48, and 60 hours
AUC0-inf	Area under the concentration vs. time curve, from time of first dosing to infinity	Pre-Deose: -1 hour, -0.5 hour and Post-Dose 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 32, 36, 40, 48, and 60 hours
Cmax	Maximum reported concentration. Estimated for both baseline	Pre-Deose: -1 hour, -0.5 hour and Post-Dose 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 32, 36, 40, 48, and 60 hours

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Tmax	Time at which Cmax is first observed	Pre-Deose: -1 hour, -0.5 hour and Post-Dose 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 32, 36, 40, 48, and 60 hours
Kel	Apparent first order terminal elimination rate constant determined from the terminal log-linear concentration-time data	Pre-Deose: -1 hour, -0.5 hour and Post-Dose 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 32, 36, 40, 48, and 60 hours
T 1/2	Terminal elimination half-life	Pre-Deose: -1 hour, -0.5 hour and Post-Dose 1, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 32, 36, 40, 48, and 60 hours

Collaborators and Investigators

• Sponsor: Amneal Pharmaceuticals, LLC
• Collaborators: Phase One Solutions, Inc.
• Investigators: Principal Investigator: Lawrence Galitz, MD, Phae 1 Solutions

Study record dates

Study Major Dates

• Study Start: March 1, 2014
• Primary Completion (Actual): March 1, 2014
• Study Completion (Actual): May 1, 2014

Study Registration Dates

• First Submitted: April 8, 2014
• First Submitted That Met QC Criteria: April 8, 2014
• First Posted (Estimate): April 10, 2014

Study Record Updates

• Last Update Posted (Estimate): June 26, 2014
• Last Update Submitted That Met QC Criteria: June 25, 2014
• Last Verified: June 1, 2014

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Endocrine System Diseases; Gonadal Disorders; Hypogonadism; Physiological Effects of Drugs; Antineoplastic Agents; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Antineoplastic Agents, Hormonal; Androgens; Anabolic Agents; Testosterone; Methyltestosterone; Testosterone undecanoate; Testosterone enanthate; Testosterone 17 beta-cypionate
• Other Study ID Numbers: AL1401